Showing 486 results

Filters Content type: News, Editors' picks Topic: Resistance

Poor adherence and the subsequent development of drug resistance is one reason why HIV treatment can fail. A drug-resistant HIV strain is one which is less susceptible to the effects of one or more anti-HIV drugs.

HIV treatment

Top 10 HIV Clinical Developments of 2019

Editor's pick
TheBodyPro
27 November 2019
PrEP science

How do we deal with apparent cases of PrEP failure?

News
15 November 2019
Resistance

FDA authorizes marketing of first next-generation sequencing test for detecting HIV-1 drug resistance mutations

Editor's pick
Food & Drug Administration
6 November 2019
New & experimental HIV treatments

Ibalizumab monoclonal antibody is effective in real-world use

News
7 October 2019
Changing treatment

‘Alarming’ rates of second-line HIV treatment failure in sub-Saharan Africa

Editor's pick
Avert
22 August 2019
People with limited treatment options

Dramatic decline in proportion of people with extensive resistance to anti-HIV medications

News
6 August 2019
Resistance

Alarming surge in drug-resistant HIV uncovered

Editor's pick
Nature
3 August 2019
People with limited treatment options

Clinical and Economic Effects of Ibalizumab for Multidrug-Resistant HIV

Editor's pick
Infectious Disease Advisor
2 August 2019
People with limited treatment options

EMA panel recommends ibalizumab for multidrug-resistant HIV-1

Editor's pick
Medscape (requires free registration)
30 July 2019
HIV treatment for children & young people

Without frequent viral load monitoring dolutegravir-based regimens not the best choice for African youth on failing ART

News
30 July 2019
Changing treatment

Biktarvy Suppresses HIV Well in Women and Those With Drug Resistance

Editor's pick
POZ
29 July 2019
Starting treatment

ADVANCE trial shows dolutegravir is highly effective in South Africa

News
25 July 2019
Resistance

WHO: Pretreatment HIV drug resistance exceeds 10% in many places

Editor's pick
Healio
24 July 2019
People with limited treatment options

AIDS Conference Returns to Mexico City, Where We Saw an Underrated, Great Advance in HIV Therapy

Editor's pick
NEJM Journal Watch
24 July 2019
Changing treatment

Drug-Resistance Mutations May Curb Efficacy of Dolutegravir-Based Regimens in Zimbabwe Teens With HIV

Editor's pick
Medscape (free registration required)
7 July 2019
Resistance

Genotype Testing at HIV Diagnosis Provides No Benefit

Editor's pick
Infectious Disease Advisor
25 June 2019
People with limited treatment options

ART for treatment-experienced people with virological failure can omit NRTIs if three active drugs available

News
13 June 2019
Health monitoring in resource-limited settings

Significant health gains from faster switching to second-line ART in sub-Saharan Africa

News
29 May 2019
Opportunistic infections

A Mysterious Infection, Spanning the Globe in a Climate of Secrecy

Editor's pick
New York Times
8 April 2019
Changing treatment

Dolutegravir-based second-line ART achieves excellent virological outcomes even in the presence of resistance to recycled NRTIs

News
13 March 2019
People with limited treatment options

Can high-dose dolutegravir be a rescue therapy?

Editor's pick
CATIE
12 March 2019
Resistance

One in six South Africans drug resistant before starting HIV treatment

News
11 March 2019
PrEP science

How many people who have used PrEP get HIV the same year? New York study finds out

News
7 March 2019
Resistance

South Africa reports successful third-line HIV treatment programme

News
4 January 2019